Thyroid cancers harboring genetic rearrangements involving NTRK1/3 (~2% of PTC) can respond to treatment with TRK inhibitors, including FDA-approved larotrectinib and entrectinib (72, 93–95). Here, NTRK1 is linked to thyroid gland carcinoma.